Stroke prophylaxis in patients non-valvular atrial fibrillation: modern approaches to anticoagulation

Napalkov D.A.; Sokolova A.A.; Zhilenko A.V.

doi:https://doi.org/

Napalkov D.A.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Minzdrava Rossii

Sokolova A.A.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Minzdrava Rossii

Zhilenko A.V.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Minzdrava Rossii

Stroke prophylaxis in patients non-valvular atrial fibrillation: modern approaches to anticoagulation

Authors:

Napalkov D.A., Sokolova A.A., Zhilenko A.V.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(5): 4‑10

Read: 2203 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Napalkov DA, Sokolova AA, Zhilenko AV. Stroke prophylaxis in patients non-valvular atrial fibrillation: modern approaches to anticoagulation. Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(5):4‑10. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

References:

Baber U., Howard V.J., Halperin J.L. et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Circ Arrhythm Electrophysiol 2011; 4: 26-32.
Banerjee A., Lane D.A., Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fibrillation population: a modeling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
Camm A.J. Atrial fibrillation and risk. Clin Cardiol 2012; 35, Suppl 1: 1-2.
Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J 2010; 31: 2369-2429.
Camm A.J., Lip G.Y.H., De Caterina R. Guidelines for the management of atrial fibrillation: Focused update of the ESC Guidelines An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med 2009; 361: 1139-1151.
Eikelboom J.W., O'Donnell M., Yusuf S. et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159: 348-353.
Gage B.F., Van Walraven C., Pearce L. et al. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-2292.
Granger C.B., Alexander J.H., McMurray J.J.V. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
Harder S. Renal profiles of anticoagulants. J Clin Pharmacol 2011; 52: 964-975.
Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
Kubitza D., Becka M., Mueck W. et al. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral direct Factor Xa inhibitor. Blood 2006; 108: 905.
Kubitza D., Becka M., Voith B. et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
Lip G.Y., Frison L., Halperin J.L., Lane D.A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180.
Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-1539.
Nakagawa K., Hirai T., Takashima S. et al. Chronic kidney disease and CHADS (2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol 2011; 107: 912-916.
Paikin J.S., Eikelboom J., Cairns J.A., Hirsh J. New antithrombotic agents insights from clinical trials. Nat Rev Cardiol 2010; 7: 498-509.
Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Eng J Med 2011; 365: 883-891.
Summary of Product Characteristics Rivaroxaban. Annex 1. http://www.xarelto.com/html/ downloads/ Xarelto_Summary_of_Product_ Characteristics_30 Sept 2008
Turagam M.K., Velagapudi P., Leal M.A., Kocheril A.G. Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease. An era of new anticoagulants. Expert Rev Cardiovasc Ther 2012; 10: 433-439.